U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06809010) titled 'GrouP O WholE BlooD : StoragE LeSion ImpacT and InfLammation' on Jan. 08.
Brief Summary: "Etablissement Francais du Sang" (EFS) prepares labile blood products from blood donations that are separated by type (red blood cells, plasma and platelets).
The "Centre de Transfusion Sanguine des Armees" (CTSA) produces an innovative labile blood product, LTO-WB, corresponding to group O leukocyte-free whole blood.
The objective of the PEDESTAL EFS study is to compare the inflammatory and biological characteristics of blood products prepared by the EFS vs. the labile blood product prepared by the CTSA.
Study Start Date: Feb., 2025
Study Ty...